1 Min Read
April 25 (Reuters) - Glenmark Pharmaceuticals Ltd:
* Glenmark Pharmaceuticals initiates clinical investigation for GBR 310, its proposed biosimilar candidate for Xolair® Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.